A new addition to your Premium newsletter today as we kick off our licensing agreement with the FT. The piece republished below offers an insight into what Western Europe is reading today about the Zuma conviction. On the same tack, you may also enjoy my interview yesterday with Accountability Now’s Adv Paul Hoffman.
For clarity – our partnership with the FT entitles BizNews to republish a certain number of its articles. Unfortunately, it does NOT entitle our Premium members to access FT.com as part of their BizNews subscription. That applies only to our partnership with the Wall Street Journal. If you have not yet triggered your WSJ sub (retails at $26 a month) there’s guidance on how to do so at the bottom of this mail.
* Meta-analysis by the American Journal of Therapeutics of 60 studies has given a big thumbs up to Ivermectin as a shield against COVID. Rubin van Niekerk’s in-depth report on the study is on BizNews.com this morning. Also, click here for the MedicalBrief report on the same study. Rounding off a forgettable news day for SA’s anti-Ivermectin Health Professionals Council is MedicalBrief’s publication of a High Court judgement which it describes as “a judicial tongue lashing” for the HPCSA.
___STEADY_PAYWALL___
* Along similar lines, the WSJ’s hard hitting columnist James Freeman revisits US government funding of “gain of function” research at the Wuhan Lab – blamed for creating COVID-19 – caustically asking “What Would We Do Without Experts?”
* On investment markets, Didi Global – the “Chinese Uber” – had a mixed start to life as a US listed company last night. Its shares kicked off 19% higher than the IPO price but slid through the day to finish only 1% better. Our partners at The Wall Street Journal have also done a good summary of the US market’s record close as the first half of 2021 ends.
* For some reading off the financial track, headline news in the US today is sex-crime convicted comedian Bill Cosby’s early release from jail after a court found in his favour; and why England is on track for the final of the Euro soccer tournament.
NB FOR YOUR WALL STREET JOURNAL ACCESS…
As a Premium subscriber you are entitled to full membership of wsj.com (normal price $29 a month). Be sure to action your access through the Premium link on the BizNews website. Because of The Wall Street Journal’s credential requirements, be sure to create a password which has at least 8 characters and includes at least one letter and one number – NB it MAY NOT contain any special characters (ie #, !, @ etc). To maintain access to WSJ.com, you MUST enter our partner’s website via BizNews Premium at least once a month. A final PS, if you had previously signed up for WSJ you’ll need to clear the cookies from your device. Our help desk can assist – [email protected].
